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TRPML1 (mucolipin 1, also known as MCOLN1) is predicted to be an intracellular late endosomal and lysosomal ion channel protein that belongs to the mucolipin subfamily of transient receptor potential (TRP) proteins [1] [2] [3] . Mutations in the human TRPML1 gene cause mucolipidosis type IV disease (ML4) 4, 5 . ML4 patients have motor impairment, mental retardation, retinal degeneration and iron-deficiency anaemia. Because aberrant iron metabolism may cause neural and retinal degeneration 6, 7 , it may be a primary cause of ML4 phenotypes. In most mammalian cells, release of iron from endosomes and lysosomes after iron uptake by endocytosis of Fe 31 -bound transferrin receptors 6 , or after lysosomal degradation of ferritin-iron complexes and autophagic ingestion of ironcontaining macromolecules 6, 8 , is the chief source of cellular iron. The divalent metal transporter protein DMT1 (also known as SLC11A2) is the only endosomal Fe 21 transporter known at present and it is highly expressed in erythroid precursors 6, 9 . Genetic studies, however, suggest the existence of a DMT1-independent endosomal and lysosomal Fe 21 transport protein 9 . By measuring radiolabelled iron uptake, by monitoring the levels of cytosolic and intralysosomal iron and by directly patch-clamping the late endosomal and lysosomal membrane, here we show that TRPML1 functions as a Fe 21 permeable channel in late endosomes and lysosomes. ML4 mutations are shown to impair the ability of TRPML1 to permeate Fe 21 at varying degrees, which correlate well with the disease severity. A comparison of TRPML1 2/2 ML4 and control human skin fibroblasts showed a reduction in cytosolic Fe 21 levels, an increase in intralysosomal Fe 21 levels and an accumulation of lipofuscin-like molecules in TRPML1 2/2 cells. We propose that TRPML1 mediates a mechanism by which Fe 21 is released from late endosomes and lysosomes. Our results indicate that impaired iron transport may contribute to both haematological and degenerative symptoms of ML4 patients.
Release of Fe 21 from late endosomes and lysosomes into the cytosol is essential for cellular iron metabolism (see Supplementary  Fig. 1 ) 6 . Because TRPML1 is ubiquitously expressed (in cells of every tissue) 5 and primarily localized in the late endosome and lysosome (LEL) 1, 3, 10 , we propose that TRPML1 may act as an endolysosomal Fe 21 release channel. The intracellular localization of wild-type TRPML1 (refs 1, 3 and 10; see also Supplementary Fig. 2 ), however, makes it difficult to assay the function of this channel. To overcome this problem, we recently developed a functional assay for TRPML channels 11 . A spontaneous mouse mutation (A419P) 12 markedly increases TRPML3-mediated currents at the plasma membrane without altering its permeation properties 11 . Mice carrying this mutation (varitint-waddler, Va) are deaf and show skin pigmentation defects. When the Va mutation (proline substitution) was introduced into a homologous position in TRPML1 (V432P), the mutant channel
TRPML1
Va was (mis)localized in many cellular compartments including both LEL and the plasma membrane ( Supplementary  Fig. 2) . Notably, TRPML1
Va , but not wild-type TRPML1, generated a cationic whole-cell current that can be measured by patch clamp 11 . We studied TRPML proteins by transiently expressing them in HEK293T cell lines. To monitor expression, TRPML channels were fused to enhanced green fluorescent protein (EGFP) at their amino termini. In response to a voltage step protocol, TRPML1
Va -expressing cells showed strong inwardly rectifying step currents ( Fig. 1a and Supplementary Fig. 3 ) in a standard extracellular bath solution (a modified Tyrode's solution). TRPML1 Va -mediated current (I TRPML1 Va) was 101 6 8.6 pA pF 21 at 280 mV (mean 6 s.e.m., n 5 48). To mimic the acidic environments of lysosomes where the extracellular side (analogous to the intralysosomal luminal side) of the wild-type TRPML1 protein is exposed to, extracellular solutions were adjusted to pH 4.6. No sizable inward current was detected when N-methyl-D-glucamine (NMDG 1 ) was the only major cation in the bath (pH 4.6; Fig. 1b Supplementary Fig. 4 ).
Both I Fe/TRPML1 Va ( Fig. 1e ) and I TRPML1 Va 11 were enhanced at low pH. Compared to experiments conducted at physiological pH (7.4), I Fe/TRPML1 Va was enhanced ,2-fold at pH 4.6 (approximately the luminal pH of lysosomes). In cells transfected with TRPML2
Va (a short splice variant; see Methods), a large current (23.0 6 3.8 pA pF 21 at 280 mV, n 5 7) was evoked by 30 mM Fe 21 (pH 4.6, Fig. 1e ). Similar to I TRPML1 Va, I TRPML2 Va was also strongly potentiated by low pH (Supplementary Fig. 5 ). The ratio of I Fe /I Tyrode for TRPML2 Va was 139 6 22% (at 280 mV, n 5 7), which was even larger than the ratio for TRPML1 Va (72 6 7%, n 5 11). In contrast with TRPML1
Va and TRPML2 Va , the ratio of I Fe /I Tyrode for TRPML3
Va was only 2.3 6 0.2% (n 5 8; Fig. 1f (Fig. 2a and Supplementary  Fig. 11 ), although the protein expression levels and subcellular localization pattern of these mutants were similar to those of the parental TRPML1
Va protein ( Supplementary Figs 12 and 13 ). Patients carrying these mutations are reported to have severe phenotypes 5, 15 . On the other hand, a large I Fe was detected in F408D-TRPML1 Va -transfected cells. The average current density of this mutant, however, was still significantly smaller than I Fe/TRPML1 Va. Patients carrying the F408D mutation have unusually mild phenotypes 13, 15 . Small but evident I Fe was detected with expression of two other mutants (R403C and F465L). A patient carrying the R403C mutation was reported to have a relatively mild phenotype 14 . Taken together, these results 
Fe 2+ uptake (fold) Fig. 2d, f) (Fig. 2f) . In contrast, R403C-TRPML1 Va (Fig. 2g) and F465L-TRPML1 Va showed no response to the addition of 1 mM Fe 21 . However, a higher concentration of Fe 21 (10 mM) induced a slow but significant quenching. These results agree with the electrophysiological measurements of ML4 mutants, as well as the disease severity of ML4 patients carrying Fig. 3a and Supplementary Fig. 15 ; see Methods). In TRPML1
Va -positive enlarged LEL, large inwardly rectifying currents were seen under the lysosome-attached configuration (Fig. 3b, c) . The currents became smaller when the patch was excised (lysosome luminalside-out) and exposed to Tyrode's solution (Fig. 3c) . These large inwardly rectifying currents were not seen in TRPML1
Va -negative vacuoles, suggesting that these lysosomal currents are mediated by TRPML1
Va (hereafter referred to as lysosomal I TRPML1 Va). Note that inward lysosomal currents are actually currents that flow out of the lysosomes. Similar to I TRPML1 Va recorded at the plasma membrane, lysosomal I TRPML1 Va was impermeable to NMDG 1 and H
1
, but was potentiated by low pH or by removal of divalent cations in the bath solution (nominal divalent-free; Fig. 3d, e) . When the luminal-sideout patches were exposed to 30 mM or 105 mM Fe 21 solutions (pH 4.6), smaller and less rectifying currents were seen, resembling I Fe/TRPML1 Va at the plasma membrane. These results indicate that TRPML1
Va behaves similarly at both plasma and lysosomal membranes. Likewise, ML4 mutant TRPML1
Va channels also behaved similarly as their plasma membrane counterparts ( Supplementary  Fig. 16 ), consistent with our conclusion that ML4 mutations primarily affect the channel function of TRPML1.
Next we performed whole-lysosome recordings on enlarged LEL expressing wild-type TRPML1 and TRPML1
Va . Significant inwardly rectifying currents were seen in wild-type TRPML1-positive LEL (81.0 6 9.0 pA pF 21 at 2120 mV, n 5 6; Fig. 3g ) with nominal divalent-free solution in the luminal side (that is, pipette solution), although the current amplitude is still one order of magnitude smaller than the whole-lysosome current recorded from TRPML1
Va -positive LEL (1,713 6 404 pA pF 21 at 2120 mV, n 5 4; Fig. 3h ). Because we were not able to record any significant whole-cell current from wild-type TRPML1-expressing HEK293T cells 11 , our results indicate that the Va mutation affects both channel gating and trafficking (between LEL and the plasma membrane) of TRPML1. When isotonic (105 mM) Fe 21 solution was included in the luminal side of wild-type TRPML1-positive enlarged LEL, inwardly rectifying currents with very positive reversal potential were observed (18 6 4 pA pF 21 at 2120 mV, n 5 4; Fig. 3i ). Collectively, these results indicate that wild-type TRPML1 is a lysosomal Fe 21 -permeable channel, and that the Va mutation does not alter the permeation properties of the TRPML1 channel.
Retention of Fe 21 in LEL due to loss or inactivation of the Fe 21 release mechanism may result in an insufficient supply of cytosolic Fe 21 . We therefore measured the levels of free (chelatable) intracellular Fe 21 in skin fibroblasts from a ML4 patient (TRPML1
2/2
) and the non-diseased parent (TRPML1
) using a fluorescence-based iron de-quenching imaging method (see Methods) 17 . Chelatable Fe 21 levels were significantly lower in TRPML1 2/2 cells compared to the control TRPML1 1/2 cells (Fig. 4a, b) . TRPML1-deficient skin fibroblast cells show autofluorescence (Fig. 4c) at excitation wavelengths between 440 nm and 500 nm, reminiscent of accumulated lipofuscin-like substances previously reported 18 . The autofluorescence observed was primarily localized in LAMP1 (a marker for LEL)-positive compartments (Fig. 4c) , indicative of a lysosomal dysfunction in TRPML1 2/2 cells. Lipofuscin, also referred to as an 'ageing pigment', is a non-degradable oxidized polymeric substance containing proteins, lipids, carbohydrates and iron 19 . The production of lipofuscin is facilitated by increased intralysosomal Fe 21 levels 19 . Our results indicate that an accumulation of autofluorescent lipofuscinlike molecules in TRPML1 2/2 cells might result from impaired intralysosomal iron metabolism. Consistent with this, lysosomal iron staining experiments showed that TRPML1 2/2 cells had higher lysosomal iron content than control cells (Supplementary Fig. 17) .
We have demonstrated that TRPML1 has a critical role in cellular iron homeostasis by showing the cytosolic Fe 21 deficiency with concurrent intralysosomal iron overload in ML4 cells. ML4 cells show a defect in the late endocytic pathway 10, 20, 21 , suggesting that TRPML1 may be required for Ca 21 -dependent fusion or fission of LEL. However, this defect in vesicular transport cannot explain the cytosolic Fe 21 deficiency that we observed because the internalization and recycling of the transferrin receptor is normal in ML4 cells 20 , and lysosomal Fe 21 release (into the cytosol) is probably mediated directly by an iron-conducting channel/transporter, as is the case for DMT1 (ref. 22) . Therefore, by far the simplest explanation of our results is that the Fe 21 release pathway between the cytosol and the lysosome lumen is blocked or inactivated in cells with ML4 mutations. Although a ML4-induced loss of Ca 21 permeability may result in a defect in lysosomal trafficking and subsequent accumulation of various lipids in LEL, the degradation of these materials is normal 20, 21 . Therefore, these accumulated substances would become most harmful only if they are oxidized to generate lipofuscin-like non-degradable materials in the presence of high intralysosomal Fe 21 (ref. 19 ). Lipofuscin-like molecules preferentially accumulate in post-mitotic cells such as muscle cells and neurons, which are primarily affected in ML4 patients 21 . Our work suggests that lysosome-targeting iron chelators might alleviate the degenerative symptoms of ML4 patients. From the cell biology perspective, an important question to address is how TRPML channels are regulated by various cytosolic and luminal factors, and/or by proteins and lipids in the LEL membrane, especially those of which are known to be involved in endolysosomal trafficking.
METHODS SUMMARY
Endolysosomal electrophysiology. HEK293T cells were either transfected with EGFP-TRPML1 alone or co-transfected with mCherry-TRPML1 and EGFP-LAMP1 (a marker for LEL). The size of the LEL is usually ,0.5 mm, which is suboptimal for patch clamping. We therefore treated cells with 1 mM vacuolin-1 (for 1-2 h), a small chemical known to increase the size of endosomes and lysosomes selectively 23 . Large vacuoles (up to 3 mm; capacitance 5 321 6 101 fF, n 5 11) were observed in most vacuolin-treated cells (Supplementary Fig. 15 ). Occasionally, enlarged LEL could also been obtained from TRPML1-transfected cells without vacuolin-1 treatment. No significant difference in TRPML channel properties was seen for enlarged LEL with or without vacuolin-1 treatment. The vacuoles that were positive for both mCherry-TRPML1 and EGFP-LAMP1 were considered as enlarged LEL. Whole-lysosome, lysosome-attached and lysosome luminal-side-out recordings were performed on isolated enlarged LEL, similar to what was performed in enlarged endosomes 24 . In brief, a patch pipette (electrode) was pressed against a cell and then quickly pulled away from the cell to slice the cell membrane. Enlarged LEL were released into the dish and identified by monitoring the TRPML1-EGFP, the TRPML1-mCherry or the LAMP1-EGFP fluorescence. Iron quenching imaging. HEK293T cells were loaded with 5 mM Fura-2 AM (Molecular Probes) in culture medium at 37 uC for 60 min. Cells were washed in Tyrode's solution for 10-30 min and fluorescence intensity at wavelength 360 nm (F 360 ) was recorded on an EasyRatioPro system (Photon Technology International). EGFP-positive cells were identified by monitoring fluorescence intensity at wavelength 470 nm (F 470 ). Images were analysed using ERP software.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Molecular biology and biochemistry. Full-length mouse TRPML1 and TRPML3, and a short splicing variant of mouse TRPML2 (GeneBank accession NP_001005846), were cloned into the EGFP-C2 vector (Clontech), the mCherry vector, or haemagglutinin-tag containing pcDNA3 as described previously 11 . No significant functional difference was observed among EGFP-tagged, mCherrytagged and haemagglutinin-tagged TRPML Va constructs. ML4 mutants were constructed on a TRPML1
Va background using a site-directed mutagenesis kit (Qiagen). All constructs were confirmed by sequencing analysis and protein expression was verified by western blotting. HEK293T cells were transiently transfected with wild-type TRPML1, TRPML1
Va and ML4 mutants for electrophysiology, confocal imaging, 55 Fe 21 uptake and Fe 21 quenching assays. TRPML1 western blot analyses were performed with an anti-EGFP monoclonal antibody (Covance). Confocal imaging. All images were taken using a Leica (TCS SP5) confocal microscope. LAMP1 antibody was from the Iowa Hybridoma Bank and LysoTracker was from Molecular Probes (Invitrogen). Mammalian cell electrophysiology. Recordings were performed in transiently transfected HEK293T cells. Cells were cultured at 37 uC, transfected using Lipofectamine 2000 (Invitrogen) and plated onto glass coverslips. No significant difference was observed for EGFP-tagged versus untagged TRPML1 ] o 5 5-10 mM) for all low-pH bath solutions. Low-pH 'Tyrode's' solution contained 150 mM Nagluconate, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, 10 mM HEPES and 10 mM MES (pH 4.6). NMDG 1 solution contained 160 mM NMDG, 20 mM HEPES, 10 mM glucose (pH 7.4). Low-pH NMDG 1 solution contained 150 mM NMDG, 10 mM glucose, 10 mM MES, 10 HEPES (pH adjusted to 4.6 using MSA). 'Isotonic' metal solutions contained 105 mM metal ions, 30 mM glucose, 10 mM HEPES, 10 mM MSA and 0-30 mM NMDG 
